Published in World J Gastroenterol on October 07, 2014
Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res (2016) 0.75
Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front Cell Infect Microbiol (2017) 0.75
Hepatitis B Virus Stimulated Fibronectin Facilitates Viral Maintenance and Replication through Two Distinct Mechanisms. PLoS One (2016) 0.75
Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective? Biomed Rep (2017) 0.75
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med (2004) 5.40
Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet (1989) 5.16
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int (2012) 4.52
Management of hepatitis B: 2000--summary of a workshop. Gastroenterology (2001) 4.17
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med (1996) 3.41
Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol (2009) 3.11
Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology (2003) 2.97
Hepatitis B genotypes and the response to interferon therapy. J Hepatol (2000) 2.97
Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther (2008) 2.90
A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology (2001) 2.80
Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology (2013) 2.66
Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus--large-scale analysis using a new genotyping method. J Infect Dis (1997) 2.61
Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut (2004) 2.59
High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol (2008) 2.56
Hepatitis B virus genotypes. Vaccine (2005) 2.56
The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med (2007) 2.52
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol (2001) 2.36
A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol (2009) 2.20
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (1999) 2.16
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
New complex recombinant genotype of hepatitis B virus identified in Vietnam. J Virol (2008) 1.95
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology (2002) 1.88
Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis (1999) 1.84
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology (2003) 1.78
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther (2006) 1.53
Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol (1999) 1.52
Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis (2008) 1.48
The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol (2001) 1.39
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut (2005) 1.28
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol (2006) 1.24
Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol (2002) 1.23
Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology (2000) 1.22
Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther (2008) 1.13
Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer (1998) 1.06
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. J Viral Hepat (2009) 1.06
Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol (1996) 1.03
Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials. Int J Cancer (2011) 0.99
The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat (1998) 0.91
Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues. Liver Int (2013) 0.90
New paradigms for the treatment of chronic hepatitis B. J Gastroenterol Hepatol (2008) 0.89
Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol (2009) 0.88
Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H. J Med Virol (2009) 0.88
Long-term follow-up of Japanese patients with chronic hepatitis B treated with interferon-alpha. Int J Mol Med (2005) 0.84
Long-term effect of interferon therapy on incidence of cirrhosis and hepatocellular carcinoma in Thai patients with chronic hepatitis B. Southeast Asian J Trop Med Public Health (2001) 0.82
Early response to interferon alpha treatment and long-term clinical outcome in Japanese patients with chronic HBV genotype C infection. Int J Mol Med (2004) 0.82
Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat (2005) 0.82
HBV genotype F: natural history and treatment. Antivir Ther (2013) 0.81
Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression. Hepatol Res (2011) 0.77
Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B. Am J Gastroenterol (1996) 0.76